Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success

被引:8
作者
Armstrong, April W. W. [1 ]
Soong, Weily [2 ,3 ]
Bernstein, Jonathan A. A. [4 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA
[2] Alabama Allergy & Asthma Ctr, Birmingham, AL USA
[3] Clin Res Ctr Alabama, Birmingham, AL USA
[4] Univ Cincinnati, Dept Internal Med, Div Immunol, Allergy Sect,Coll Med, Cincinnati, OH USA
关键词
Medical dermatology; Outcome measurement; Patients; Quality of life; Urticaria; QUALITY-OF-LIFE; REPORTED OUTCOME INSTRUMENT; IMPORTANT DIFFERENCE; DISEASE-ACTIVITY; DOUBLE-BLIND; OMALIZUMAB; VALIDATION; COMBINATION; EFFICACY; IMPACT;
D O I
10.1007/s13555-023-00955-7
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Chronic spontaneous urticaria (CSU) is a complex skin disease characterized by the spontaneous appearance of wheals, angioedema, or both, for more than 6 weeks. Many patients experience a relapsing-remitting disease course for years. Owing to the unpredictability of wheal recurrence and the severity of pruritis, patients suffer considerable impairment in their quality of life. Physicians face multiple challenges, not least of which is a lack of clear guidance on what constitutes "treatment success". There is a lack of awareness of which measures should be used to best assess the various aspects of CSU, including disease activity, disease control, and quality of life-which themselves each comprise multiple components-and how to apply the results of each score to treatment decision-making. Although the overarching aim of treatment is for patients to be completely free of signs and symptoms of CSU, a more realistic definition of "treatment success" is needed to guide ongoing, long-term disease management for each individual patient. In this review, we consider what lessons can be learned from the current evidence base to provide further direction toward a universal definition of "treatment success".
引用
收藏
页码:1629 / 1646
页数:18
相关论文
共 68 条
  • [1] [Anonymous], 2017, RANDOMIZED CLIN TRIA
  • [2] [Anonymous], 2022, clinicaltrials.gov
  • [3] [Anonymous], 2020, Clinicaltrials.gov
  • [4] [Anonymous], 2019, ClinicalTrials.gov
  • [5] A new tool to evaluate the impact of chronic urticaria on quality of life:: chronic urticaria quality of life questionnaire (CU-Q2oL)
    Baiardini, I
    Pasquali, M
    Braido, F
    Fumagalli, F
    Guerra, L
    Compalati, E
    Braga, M
    Lombardi, C
    Fassio, O
    Canonica, GW
    [J]. ALLERGY, 2005, 60 (08) : 1073 - 1078
  • [6] Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature Review
    Balp, Maria-Magdalena
    Halliday, Anna C.
    Severin, Thomas
    Leonard, Saoirse A.
    Partha, Gautam
    Kalra, Manik
    Marsland, Alexander M.
    [J]. DERMATOLOGY AND THERAPY, 2022, 12 (01) : 15 - 27
  • [7] Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatogy Life Quality Index (DLQI): Further Data
    Basra, M. K. A.
    Salek, M. S.
    Camilleri, L.
    Sturkey, R.
    Finlay, A. Y.
    [J]. DERMATOLOGY, 2015, 230 (01) : 27 - 33
  • [8] Benralizumab for Chronic Spontaneous Urticaria
    Bernstein, Jonathan A.
    Singh, Umesh
    Rao, Marepalli B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) : 1389 - 1391
  • [9] Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of "real-world' evidence
    Bernstein, Jonathan A.
    Kavati, Abhishek
    Tharp, Michael D.
    Ortiz, Benjamin
    MacDonald, Karen
    Denhaerynck, Kris
    Abraham, Ivo
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (04) : 425 - 448
  • [10] Autologous serum and plasma skin test to predict 2-year outcome in chronic spontaneous urticaria
    Boonpiyathad, Tadech
    Sangasapaviliya, Atik
    [J]. ASIA PACIFIC ALLERGY, 2016, 6 (04) : 226 - 235